尿毒症继发性甲状旁腺功能亢进症的治疗研究进展
摘要
继发性甲状旁腺功能亢进症(SHPT)是一种与慢性肾脏疾病(CKD)相关的主要并发症,几乎所有需要透析治疗的尿毒症患者都会受到它的影响。它可引起血液、心血管、骨骼、神经等多系统损害,严重影响患者的生活质量甚至威胁生命。到目前为止,SHPT的治疗方法尚未有定论。本文对尿毒症患者SHPT的治疗研究进展作一综述。
引文
[1]Sanchez CP,Goodman WG,Salusky IB.Prevention of renal osteodystrophy in predialysis patients[J].Am J Med Sci,1999,317(6):398-404.
[2]S1iver J,Naveh-Many T.FGF-23 and the parathyroid[J].Endocrine FGFs and Klothos,2012,6:92-99.
[3]Zhang Ling.Strategy for the treatment of secondary hyperparathyroidism[J].Chin J Kid Dis Invest(Electr Ver),2015,4(3):5-9.
[4]Kidney disease:improving global outcomes(KDIGO)CKD-MBD update work group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7:1-59.
[5]Tentori F,Wang M,Bieber BA,et al.Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis:the DOPPS study[J].Clin J Am Soc Nephrol,2014,10(1):98-109.
[6]Waheed AA,Pedraza F,Lenz O,et al.Phosphate control in end-stage renal disease:barriers and opportunities[J].Nephrol Dial Transplant,2013,28(12):2961-2968.
[7]Salam SN,Khwaja A,Wilkie ME.PharmacologicalManagement of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease[J].Drugs,2016,76(8):841-852.
[8]Karavetian M,de Vries N,Elzein H,et al.Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients,Lebanon[J].Patient Educ Couns,2015,98(9):1116-1122.
[9]Lacson E Jr,Xu J,Suri RS,et al.Survival with three-times weekly in-center nocturnalversus conventional hemodialysis[J].J Am Soc Nephrol,2012,23(4):687-695.
[10]罗丽花,管保章,黄盛玲,等.维持性血液透析患者钙磷代谢紊乱治疗进展[J].临床肾脏病杂志,2015,15(9):567-570.
[11]Salam SN,Khwaja A,Wilkie ME.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease[J].Drugs,2016,76(8):841-852.
[12]Wang C,Liu X,Zhou Y,et al.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients:A Meta-Analysis of Randomized Controlled Trials[J].PLOS One,2015,10(7):e0133938.
[13]田雪,全蕾,许戎,等.限磷饮食下碳酸镧与醋酸钙降低腹膜透析患者高磷血症的效果比较[J].中国血液净化,2016,15(5):269-274.
[14]Jamal SA,Vandermeer B,Raggi P,et al.Effect of calciumbased versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease:an updated systematic review and meta-analysis[J].Lancet,2013,382(9900):1268-1277.
[15]Shigematsu T,Ohya M,Negi S,et al.Safety and efficacy evaluation oflanthanumcarbonate for hyperphosphatemia in end-stage renal disease patients[J].Contrib Nephrol.2015,185:42-55.
[16]Daugirdas JT,Finn WF,Emmett M,et al.The phosphate binder equivalent dose[J].Semin Dial,2011,24(1):41-49.
[17]Sprague SM,Wetmore JB,Gurevich K,et al.Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism[J].Clin J Am Soc Nephrol,2015,10(6):1021-1030.
[18]Vlassara H,Uribarri J,Cai W,et al.Effects of sevelamer on HbA1c,inflammation,and advanced glycation end products in diabetic kidney disease[J].Clin J Am Soc Nephrol,2012,7(6):934-942.
[19]Wang C,Liu X,Zhou Y,et al.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients:A Meta-Analysis of Randomized Controlled Trials[J].PLoS One,2015,10(7):e0133938.
[20]Phan O,MaiIlard M,Peregaux C,et al.PA21,a new ironbased noncalcium phosphate binder,prevents vascular calcification in chronic renal failure rate[J].J Pharmacol Exp Ther,2013,346(2):281-289.
[21]Yaguchi A,Tatemichi S,Takeda H,et al.PA21,a novel phosphate binder,improves renal osteodystrophy in rats with chronic renal failure[J].PLoS One,2017,12(7):e0180430
[22]程叙扬,甘红兵,吕继成,等.药用活性炭有效降低顽固性高磷血症透析患者血磷水平与钙磷乘积[J].中华肾脏病杂志,2012,28(1):21-24.
[23]Chang TI,Abdalla S,London GM,et al.The effects of cinacalcet on blood pressure,mortality and cardiovascular endpoints in the EVOLVE trial[J].J Hum Hypertens,2016,30(3):204-209.
[24]Tanaka M,Yoshida K,Fukuma S,et al.Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia:Results from the MBD-5D Study[J].PLoS One,2016,11(10):e0164865.
[25]Moe SM,Chertow GM,Parfrey PS,et al.Cinacalcet,fibroblast growth factor-23,and cardiovascular disease in hemodialysis:the evaluation of cinacalcet hcl therapy to lower cardiovascular events(EVOLVE)trial[J].Circulation,2015,132(1):27-39.
[26]Zitt E,Rix M,Fouque D,et al.Effectiveness of cinacalcet inpatients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy:results of the ECHO study[J].Nephrol Dial Transplant,2011,26(6):1956-1961.
[27]P e rez-Ricart A,Galicia-Basart M,Alcalde-Rodrigo M,et al.Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis[J].PLoS One,2016,11(9):e0161527.
[28]Martin K,Block G,Cheng S,et al.Comparison of the efficacy and safety of intravenous(IV)etelcalcetide(AMG 416)and oralcinacalcet(CIN)in patients on hemodialysis(HD)with secondary hyperparathyroidism(SHPT)[J].J Am Soc Nephrol,2015,26:B9.
[29]Shigematsu T,Fukagawa M,Yokoyama K,et al.Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism[J].Clinical&Experimental Nephrology,2017,22(2):1-11.
[30]Cozzolino M,Galassi A,Conte F,et al.Treatment of secondary hyperparathyroidism:the clinical utility of etelcalcetide[J].Ther Clin Risk Manag,2017,13:679-689.
[31]吴慧,邱晓楠,尹忠诚.磷结合剂、Vit D类、钙敏感受体激动剂的合理搭配[J].中国血液净化,2017,16(4):152-154.
[32]张李刚,张春天,王丽芳,等.西那卡塞辅治血液透析继发性甲状旁腺功能亢进患者效果观察[J].疑难病杂志,2016,15(12):1242-1245.
[33]于明安,张凌,彭丽丽,等.超声引导微波消融术治疗继发性甲旁亢短期疗效分析[J].中华肾脏病杂志,2015,31(4):303-304.
[34]戎吉龙,陈建生.介入与手术治疗继发性甲状旁腺功能亢进的疗效分析[J].现代实用医学,2017,29(3):338-340.
[35]Apetrii M,Goldsmith D,Nistor I,et al.Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder(CKD-MBD)-A systematic review and metaanalysis[J].PLoS One,2017,12(11):e0187025.
[36]Chen J,Zhou QY,Wang JD.Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure:a meta-analysis[J].Horm Metab Res,2015,47(9):643-651.
[37]Liu ME,Qiu NC,Zha SL,et al.To assess the effects of parathyroidectomy(TPTX versus TPTX+AT)for Secondary Hyperparathyroidism in chronic renal failure:A Systematic Review and Meta-Analysis[J].Int J Surg,2017,44:353-362.
[38]Magnabosco FF,Tavares MR,Montenegro FL.Surgical treatment of secondary hyperparathyroidism:a systematic review of the literature[J].Arq Bras EndocrinolMetabol,2014,58(5):562-571.
[39]王海峰,张凌,姚力,等.三种不同甲状旁腺切除术治疗继发性甲状旁腺功能亢进425例疗效比较[J].中国血液净化,2016,15(9):455-458.
[2]S1iver J,Naveh-Many T.FGF-23 and the parathyroid[J].Endocrine FGFs and Klothos,2012,6:92-99.
[3]Zhang Ling.Strategy for the treatment of secondary hyperparathyroidism[J].Chin J Kid Dis Invest(Electr Ver),2015,4(3):5-9.
[4]Kidney disease:improving global outcomes(KDIGO)CKD-MBD update work group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7:1-59.
[5]Tentori F,Wang M,Bieber BA,et al.Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis:the DOPPS study[J].Clin J Am Soc Nephrol,2014,10(1):98-109.
[6]Waheed AA,Pedraza F,Lenz O,et al.Phosphate control in end-stage renal disease:barriers and opportunities[J].Nephrol Dial Transplant,2013,28(12):2961-2968.
[7]Salam SN,Khwaja A,Wilkie ME.PharmacologicalManagement of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease[J].Drugs,2016,76(8):841-852.
[8]Karavetian M,de Vries N,Elzein H,et al.Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients,Lebanon[J].Patient Educ Couns,2015,98(9):1116-1122.
[9]Lacson E Jr,Xu J,Suri RS,et al.Survival with three-times weekly in-center nocturnalversus conventional hemodialysis[J].J Am Soc Nephrol,2012,23(4):687-695.
[10]罗丽花,管保章,黄盛玲,等.维持性血液透析患者钙磷代谢紊乱治疗进展[J].临床肾脏病杂志,2015,15(9):567-570.
[11]Salam SN,Khwaja A,Wilkie ME.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease[J].Drugs,2016,76(8):841-852.
[12]Wang C,Liu X,Zhou Y,et al.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients:A Meta-Analysis of Randomized Controlled Trials[J].PLOS One,2015,10(7):e0133938.
[13]田雪,全蕾,许戎,等.限磷饮食下碳酸镧与醋酸钙降低腹膜透析患者高磷血症的效果比较[J].中国血液净化,2016,15(5):269-274.
[14]Jamal SA,Vandermeer B,Raggi P,et al.Effect of calciumbased versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease:an updated systematic review and meta-analysis[J].Lancet,2013,382(9900):1268-1277.
[15]Shigematsu T,Ohya M,Negi S,et al.Safety and efficacy evaluation oflanthanumcarbonate for hyperphosphatemia in end-stage renal disease patients[J].Contrib Nephrol.2015,185:42-55.
[16]Daugirdas JT,Finn WF,Emmett M,et al.The phosphate binder equivalent dose[J].Semin Dial,2011,24(1):41-49.
[17]Sprague SM,Wetmore JB,Gurevich K,et al.Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism[J].Clin J Am Soc Nephrol,2015,10(6):1021-1030.
[18]Vlassara H,Uribarri J,Cai W,et al.Effects of sevelamer on HbA1c,inflammation,and advanced glycation end products in diabetic kidney disease[J].Clin J Am Soc Nephrol,2012,7(6):934-942.
[19]Wang C,Liu X,Zhou Y,et al.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients:A Meta-Analysis of Randomized Controlled Trials[J].PLoS One,2015,10(7):e0133938.
[20]Phan O,MaiIlard M,Peregaux C,et al.PA21,a new ironbased noncalcium phosphate binder,prevents vascular calcification in chronic renal failure rate[J].J Pharmacol Exp Ther,2013,346(2):281-289.
[21]Yaguchi A,Tatemichi S,Takeda H,et al.PA21,a novel phosphate binder,improves renal osteodystrophy in rats with chronic renal failure[J].PLoS One,2017,12(7):e0180430
[22]程叙扬,甘红兵,吕继成,等.药用活性炭有效降低顽固性高磷血症透析患者血磷水平与钙磷乘积[J].中华肾脏病杂志,2012,28(1):21-24.
[23]Chang TI,Abdalla S,London GM,et al.The effects of cinacalcet on blood pressure,mortality and cardiovascular endpoints in the EVOLVE trial[J].J Hum Hypertens,2016,30(3):204-209.
[24]Tanaka M,Yoshida K,Fukuma S,et al.Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia:Results from the MBD-5D Study[J].PLoS One,2016,11(10):e0164865.
[25]Moe SM,Chertow GM,Parfrey PS,et al.Cinacalcet,fibroblast growth factor-23,and cardiovascular disease in hemodialysis:the evaluation of cinacalcet hcl therapy to lower cardiovascular events(EVOLVE)trial[J].Circulation,2015,132(1):27-39.
[26]Zitt E,Rix M,Fouque D,et al.Effectiveness of cinacalcet inpatients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy:results of the ECHO study[J].Nephrol Dial Transplant,2011,26(6):1956-1961.
[27]P e rez-Ricart A,Galicia-Basart M,Alcalde-Rodrigo M,et al.Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis[J].PLoS One,2016,11(9):e0161527.
[28]Martin K,Block G,Cheng S,et al.Comparison of the efficacy and safety of intravenous(IV)etelcalcetide(AMG 416)and oralcinacalcet(CIN)in patients on hemodialysis(HD)with secondary hyperparathyroidism(SHPT)[J].J Am Soc Nephrol,2015,26:B9.
[29]Shigematsu T,Fukagawa M,Yokoyama K,et al.Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism[J].Clinical&Experimental Nephrology,2017,22(2):1-11.
[30]Cozzolino M,Galassi A,Conte F,et al.Treatment of secondary hyperparathyroidism:the clinical utility of etelcalcetide[J].Ther Clin Risk Manag,2017,13:679-689.
[31]吴慧,邱晓楠,尹忠诚.磷结合剂、Vit D类、钙敏感受体激动剂的合理搭配[J].中国血液净化,2017,16(4):152-154.
[32]张李刚,张春天,王丽芳,等.西那卡塞辅治血液透析继发性甲状旁腺功能亢进患者效果观察[J].疑难病杂志,2016,15(12):1242-1245.
[33]于明安,张凌,彭丽丽,等.超声引导微波消融术治疗继发性甲旁亢短期疗效分析[J].中华肾脏病杂志,2015,31(4):303-304.
[34]戎吉龙,陈建生.介入与手术治疗继发性甲状旁腺功能亢进的疗效分析[J].现代实用医学,2017,29(3):338-340.
[35]Apetrii M,Goldsmith D,Nistor I,et al.Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder(CKD-MBD)-A systematic review and metaanalysis[J].PLoS One,2017,12(11):e0187025.
[36]Chen J,Zhou QY,Wang JD.Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure:a meta-analysis[J].Horm Metab Res,2015,47(9):643-651.
[37]Liu ME,Qiu NC,Zha SL,et al.To assess the effects of parathyroidectomy(TPTX versus TPTX+AT)for Secondary Hyperparathyroidism in chronic renal failure:A Systematic Review and Meta-Analysis[J].Int J Surg,2017,44:353-362.
[38]Magnabosco FF,Tavares MR,Montenegro FL.Surgical treatment of secondary hyperparathyroidism:a systematic review of the literature[J].Arq Bras EndocrinolMetabol,2014,58(5):562-571.
[39]王海峰,张凌,姚力,等.三种不同甲状旁腺切除术治疗继发性甲状旁腺功能亢进425例疗效比较[J].中国血液净化,2016,15(9):455-458.